Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Among authors: sun x. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Bevacizumab for neovascular age-related macular degeneration in China.
Li X, Hu Y, Sun X, Zhang J, Zhang M; Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB). Li X, et al. Among authors: sun x. Ophthalmology. 2012 Oct;119(10):2087-93. doi: 10.1016/j.ophtha.2012.05.016. Epub 2012 Jul 20. Ophthalmology. 2012. PMID: 22818896 Clinical Trial.
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study.
Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, Chen X, Shen Y, Huang H, Yu L, Ke Z, Rosenfeld PJ, Kaiser PK, Ying G, Sun X, Xu X; PHOENIX Study Group. Liu K, et al. Among authors: sun x. Am J Ophthalmol. 2019 Jan;197:156-167. doi: 10.1016/j.ajo.2018.08.026. Epub 2018 Aug 24. Am J Ophthalmol. 2019. PMID: 30148987 Clinical Trial.
One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial.
Wang F, Yuan Y, Wang L, Ye X, Zhao J, Shen M, Zhang Q, Xu D, Qin G, Zhang W, Yuan F, Chang Q, Zhao P, Wang F, Sun X. Wang F, et al. Among authors: sun x. J Ophthalmol. 2019 Oct 10;2019:7530458. doi: 10.1155/2019/7530458. eCollection 2019. J Ophthalmol. 2019. PMID: 31687203 Free PMC article.
40,039 results
You have reached the last available page of results. Please see the User Guide for more information.